Orphelia Pharma Secures US Patent

Orphelia Pharma have announced that the US Patent and Trademark Office (USPTO) has issued patent US11/730,732 for KIZFIZO, the first pediatric and ready-to-use drinkable formulation of temozolomide.

KIZFIZO (temozolomide oral suspension, 40 mg/ml), known as Ped-TMZ or KIMOZO during its clinical development and ongoing early access programs, is specifically designed for use in the treatment of children with relapsed or refractory high-risk neuroblastoma, oncology indications with a very poor prognosis. This taste-masked oral suspension was developed for children: it allows a precise dose to be administered orally or via a nasogastric tube in a small volume. Orphelia Pharma has been developing KIZFIZO in collaboration with Gustave Roussy, the leading European cancer centre, for the last six years.

“Following the issuance of the European patent in 2021, this grant of the US patent once again highlights the innovation in the formulation of KIZFIZO, which lies in the discovery of an essential excipient improving the stability and the rheological properties of the suspension,” said Jeremy Bastid, chief development officer at Orphelia Pharma. “This US patent complements the European one already issued and the Orphan Drug Designation (ODD) obtained in the US and Europe for temozolomide in the treatment of neuroblastoma. Therefore, we benefit from a double exclusivity protection for KIZFIZO in these territories.”

“There is a major hospital need for an oral formulation of temozolomide, but attempts to generate such liquid formulations have been unsatisfactory, with low concentrations leading to large administration volumes, short shelf-lives and erratic recrystallisation,” said Maxime Annereau, pharmacist at Gustave Roussy and co-inventor of the patent. “Our work, carried out jointly with the Orphelia Pharma team, led to the identification of a formulation with a high concentration of temozolomide while controlling its polymorphic transition process.”

The granted US (US11/730,732) and European (EP3613436) patents ‘oral suspension of temozolomide’ are co-owned by Orphelia Pharma and Gustave Roussy. Based on the filing date of the priority application, the patent protection is expected to last until 2038. This protection complements the ODDs already obtained in these territories.